BGMS

#4898
Bio Green Med Solution, Inc. - Common Stock
0.8 6 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.86
0.86
Jahresspanne
0.57
6.70
Tagesänderung
-3.37%
Monatliche Änderung
-2.27%
6 month change
-10.06%
Jahresänderung
-85.67%
Vorheriger Schlusskurs
0.8 9
Open
0.8 6
Tief
0.8 6
Hoch
0.8 6
Volumen
3
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bio Green Med Solution, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bio Green Med Solution, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bio Green Med Solution, Inc. current report, Q1 FY2026
8-K

Bio Green Med Solution, Inc. current report, Q3 FY2008

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on September 4, 2008. The filing reports corporate governance changes effective as of September 4, 2008, including the appointment of a new director and an amendment to the company's bylaws.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.

Material Changes

  • Director Appointment: The Board appointed Dr. Nicholas G. Bacopoulos as a Class 3 Director effective September 4, 2008, serving until the 2009 annual meeting.
  • Compensatory Arrangement: Dr. Bacopoulos received an option to purchase 25,000 shares of common stock at an exercise price of $1.18 per share. The option vests 25% on the first anniversary and the remainder ratably over the following 36 months, expiring on September 4, 2018.
  • Director Fees: Dr. Bacopoulos is entitled to an annual fee of $20,000, plus $2,000 for each in-person Board meeting and $1,000 for each telephonic meeting.
  • Bylaw Amendment: The Board approved an amendment to the Amended and Restated Bylaws to increase the maximum number of directors from eight to nine.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document states there are no undisclosed transactions in which Dr. Bacopoulos has a material interest.

Investor Verification Checklist

  • Verify the correct registrant name is Cyclacel Pharmaceuticals, Inc., as the input metadata referenced "Bio Green Med Solution, Inc."
  • Confirm the vesting schedule and exercise price ($1.18) of the 25,000 share option granted to Dr. Bacopoulos.
  • Review the attached Press Release (Exhibit 99.1) for additional context on the director appointment.
  • Check the amended Bylaws (Exhibit 3.01) to confirm the board size increase to nine directors.